Our finding of LLT1 over expression in prostate cancer could lead to novel therapeutic strategies to eliminate prostate cancer by blocking the inhibitory signal through LLT1-NKRP1A interaction. The gene discussed is CLEC2D; the disease is Familial prostate cancer.